心臓移植治療薬の世界市場:予測及び分析 2020-2024

LINEで送る

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024
• Market outlook
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Immunosuppressants – Market size and forecast 2019-2024
• Supplementary medications – Market size and forecast 2019-2024
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Advent of techniques for organ transplantation
• Increasing strategic alliances
• Growing international collaborations for organ transplantation
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Astellas Pharma Inc.
• Cadila Healthcare Ltd.
• F. Hoffmann-La Roche Ltd.
• Mylan NV
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Veloxis Pharmaceuticals A/S
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendor key offerings
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Product – Market share 2019-2024 (%)
Exhibit 19: Comparison by product
Exhibit 20: Immunosuppressants – Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Immunosuppressants – Year-over-year growth 2020-2024 (%)
Exhibit 22: Supplementary medications – Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Supplementary medications – Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2019-2024 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 29: North America – Year-over-year growth 2020-2024 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Objectives of European Patients’ Forum
Exhibit 35: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 37: Proportion of geriatric population in Asia 2009 and 2018 (% of total population)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 40: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Benefits of multiple dosage forms of drugs
Exhibit 45: Side effects of immunosuppressants
Exhibit 46: Demand-supply imbalance of organ transplantation 2011-2015
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AbbVie Inc. – Vendor overview
Exhibit 54: AbbVie Inc. – Business segments
Exhibit 55: AbbVie Inc. – Organizational developments
Exhibit 56: AbbVie Inc. – Geographic focus
Exhibit 57: AbbVie Inc. – Key offerings
Exhibit 58: AbbVie Inc. – Key customers
Exhibit 59: Astellas Pharma Inc. – Vendor overview
Exhibit 60: Astellas Pharma Inc. – Business segments
Exhibit 61: Astellas Pharma Inc. – Organizational developments
Exhibit 62: Astellas Pharma Inc. – Geographic focus
Exhibit 63: Astellas Pharma Inc. – Key offerings
Exhibit 64: Astellas Pharma Inc. – Key customers
Exhibit 65: Cadila Healthcare Ltd. – Vendor overview
Exhibit 66: Cadila Healthcare Ltd. – Business segments
Exhibit 67: Cadila Healthcare Ltd. – Organizational developments
Exhibit 68: Cadila Healthcare Ltd. – Geographic focus
Exhibit 69: Cadila Healthcare Ltd. – Key offerings
Exhibit 70: Cadila Healthcare Ltd. – Key customers
Exhibit 71: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 72: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 73: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 74: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 75: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 76: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 77: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 78: Mylan NV – Vendor overview
Exhibit 79: Mylan NV – Business segments
Exhibit 80: Mylan NV – Organizational developments
Exhibit 81: Mylan NV – Geographic focus
Exhibit 82: Mylan NV – Segment focus
Exhibit 83: Mylan NV – Key offerings
Exhibit 84: Mylan NV – Key customers
Exhibit 85: Novartis AG – Vendor overview
Exhibit 86: Novartis AG – Business segments
Exhibit 87: Novartis AG – Organizational developments
Exhibit 88: Novartis AG – Geographic focus
Exhibit 89: Novartis AG – Segment focus
Exhibit 90: Novartis AG – Key offerings
Exhibit 91: Novartis AG – Key customers
Exhibit 92: Pfizer Inc. – Vendor overview
Exhibit 93: Pfizer Inc. – Business segments
Exhibit 94: Pfizer Inc. – Organizational developments
Exhibit 95: Pfizer Inc. – Geographic focus
Exhibit 96: Pfizer Inc. – Segment focus
Exhibit 97: Pfizer Inc. – Key offerings
Exhibit 98: Pfizer Inc. – Key customers
Exhibit 99: Sun Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 100: Sun Pharmaceutical Industries Ltd. – Business segments
Exhibit 101: Sun Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 102: Sun Pharmaceutical Industries Ltd. – Geographic focus
Exhibit 103: Sun Pharmaceutical Industries Ltd. – Key offerings
Exhibit 104: Sun Pharmaceutical Industries Ltd. – Key customers
Exhibit 105: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 106: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 107: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 108: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 109: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 110: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 111: Veloxis Pharmaceuticals A/S – Vendor overview
Exhibit 112: Veloxis Pharmaceuticals A/S – Business segments
Exhibit 113: Veloxis Pharmaceuticals A/S – Organizational developments
Exhibit 114: Veloxis Pharmaceuticals A/S – Geographic focus
Exhibit 115: Veloxis Pharmaceuticals A/S – Key offerings
Exhibit 116: Veloxis Pharmaceuticals A/S – Key customers
Exhibit 117: Validation techniques employed for market sizing
Exhibit 118: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様